<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158244</url>
  </required_header>
  <id_info>
    <org_study_id>C3991003</org_study_id>
    <nct_id>NCT05158244</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF-07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and&#xD;
      participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the&#xD;
      investigational product or placebo every day for 42 days.&#xD;
&#xD;
      The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of&#xD;
      multiple oral doses of PF-07081532 in participants with inadequately controlled type 2&#xD;
      diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">May 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent treatment-related adverse events</measure>
    <time_frame>Baseline to minimum 28 days after last administration of investigational product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant, abnormal safety laboratory tests</measure>
    <time_frame>Baseline to 7-14 days after last administration of investigational product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant, abnormal vital sign parameters</measure>
    <time_frame>Baseline to 7-14 days after last administration of investigational product</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically significant, abnormal 12-lead ECG parameters</measure>
    <time_frame>Baseline to 7-14 days after last administration of investigational product</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to 24 hours post-dose (AUC24) of PF-07081532 plasma concentration</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0 to 24 hours post-dose (AUC24) of PF-07081532 plasma concentration</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-07081532</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-07081532</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07081532</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07081532</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) of PF-07081532</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PF-07081532</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple dosing, once-daily for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>multiple dosing, once-daily for 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07081532</intervention_name>
    <description>Study Drug, once daily for 42 days</description>
    <arm_group_label>PF-07081532</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, once daily for 42 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females of non childbearing potential;&#xD;
&#xD;
          -  Patients with T2DM, inadequately controlled with metformin;&#xD;
&#xD;
          -  HbA1c ≥7.0% to ≤10.5% (for T2DM); HbA1c &lt;6.5% (for non-diabetic obese, if enrolled)&#xD;
&#xD;
          -  Total body weight &gt;50 kg (110 lbs)&#xD;
&#xD;
          -  BMI ≥24.5 to ≤45.5 kg/m2 (T2DM), BMI &gt;30.5 to ≤45.5 kg/m2 (for non-diabetic obese)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, hepatic, psychiatric, neurological, dermatological, or&#xD;
             allergic disease;&#xD;
&#xD;
          -  Medical history of T2DM (for non-diabetic obese participants, if enrolled);&#xD;
&#xD;
          -  Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes;&#xD;
&#xD;
          -  Evidence or history of clinically significant cardiovascular disease;&#xD;
&#xD;
          -  Any malignancy not considered cured;&#xD;
&#xD;
          -  Acute pancreatitis or history of chronic pancreatitis;&#xD;
&#xD;
          -  Acute gallbladder disease;&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption;&#xD;
&#xD;
          -  Personal or family history of MTC or MEN2;&#xD;
&#xD;
          -  Medical or psychiatric condition that may increase the risk of study participation;&#xD;
&#xD;
          -  Any vaccination within the 1 week prior to admission to the CRU;&#xD;
&#xD;
          -  Previous administration with an investigational drug within 30 days or 5 half-lives&#xD;
             preceding first dose;&#xD;
&#xD;
          -  Known prior participation in a trial involving PF-07081532;&#xD;
&#xD;
          -  A positive urine drug screen at screening or admission;&#xD;
&#xD;
          -  Positive testing at screening for HIV, HBsAg, HBcAb, HBsAb or HCVAb;&#xD;
&#xD;
          -  Positive COVID-19 test at screening or admission;&#xD;
&#xD;
          -  Supine BP ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic);&#xD;
&#xD;
          -  12-lead ECG clinically relevant abnormalities that may affect participant safety or&#xD;
             interpretation of study results;&#xD;
&#xD;
          -  Participants with ANY of the following abnormalities in clinical laboratory tests:&#xD;
             *AST or ALT level ≥1.5x ULN;&#xD;
&#xD;
               -  Total bilirubin level ≥1.5x ULN;&#xD;
&#xD;
               -  TSH&gt; ULN;&#xD;
&#xD;
               -  Fasting C-peptide &lt;0.8 ng/mL;&#xD;
&#xD;
               -  Serum calcitonin &gt; ULN;&#xD;
&#xD;
               -  Amylase &gt; ULN;&#xD;
&#xD;
               -  Lipase &gt; ULN;&#xD;
&#xD;
               -  eGFR &lt;60 mL/min/1.73m2 (per MDRD equation);&#xD;
&#xD;
               -  FPG &gt;270 mg/dL&#xD;
&#xD;
          -  History of alcohol abuse, binge drinking and/or any illicit drug use or dependence&#xD;
             within 6 months of Screening;&#xD;
&#xD;
          -  Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more&#xD;
             within 60 days prior to dosing;&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin induced thrombocytopenia;&#xD;
&#xD;
          -  Known intolerance to any GLP-1R agonist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3991003</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

